DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.
Through expansion in Europe, DCR will be able to facilitate the conduct of late phase clinical trials in several medical centers outside of the U.S. for the first time. Physician leaders from Germany, Poland and Portugal with a combined 20 years of research experience will collaborate with DCR to provide data and knowledge-based insights to its clients.
"Together our American and European teams provide unique expertise in clinical research," said Amy Young, vice president and general manager of DCR. "Combining extensive nephrology and clinical trial experience with knowledge of local differences in the practice of nephrology positions us as a valuable resource in drug development for chronic kidney disease management."
DCR has been involved in developing every end stage renal disease drug approved by the U.S. Federal Drug Administration in the last 15 years. Individuals with advanced kidney disease typically have comorbidities, which may cause health complications. Clinical research is a necessary step in providing high quality care to patients with impaired kidney function.
"We have an experienced group of research physicians in our organization," said Bjorn Englund, DaVita HealthCare Partners president for Europe and the Middle East. "It's important that we apply their expertise as a resource to advance care for our patients."
Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration